This conversation will focus on the PD-L1 ADC mechanism and publicly available data for SGN-PDL1V (Seagen's investigational vedotin ADC directed to the T cell checkpoint ligand, PD-(L)1) and MT-6402 (a third generation engineered toxin body currently in development by Molecular Templates).